The Food and Drug Administration has cleared Cynosure’s Cellulaze Workstation, a cellulite treatment device, for commercial distribution, the company announced.
Washington - The Food and Drug Administration has cleared Cynosure’s Cellulaze Workstation, a cellulite treatment device, for commercial distribution, the company announced.
Cellulaze uses proprietary SideLight 3D side-firing technology to target the subcutaneous herniated pockets of fat, stiffened septae and thin skin, according to a company press release. Cynosure states that a tiny laser fiber is inserted under the skin, heating it and disrupting or melting the fat. The laser releases the fibrous bands that create cellulite’s dimpling effect, creating a smoother look. The laser’s energy also stimulates collagen production to increase skin thickness and elasticity.
According to the company, nearly four years of clinical research shows that Cellulaze treatments can increase skin thickness by 25 percent and elasticity by 29 percent at one year.
Cellulaze is already marketed in Canada, the European Union, Australia and South Korea. Cynosure states it also is pursuing regulatory approvals in other international markets.
Go back to the Dermatology Times eNews newsletter.